Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Preblick

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Diabetes, Obesity & Metabolism|December 27, 2017
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulinFang Liz Zhou, Lin Xie, Chunshen Pan, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 9, 2007
Ethnic/racial variations in blood pressure awareness, treatment, and controlThomas Giles, Juan M Aranda, Dong-Churl Suh, et al.
Journal of Comparative Effectiveness Research|March 14, 2023
A value-based budget impact model for dronedarone compared with other rhythm control strategiesJennifer Ken-Opurum, Sesha Ss Srinivas, Pratyusha Vadagam, et al.
Clinical Therapeutics|June 21, 2011
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapySuellen M Curkendall, Cheng Wang, Barbara H Johnson, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United StatesVijay N Joish, Fang Liz Zhou, Ronald Preblick, et al.
Advances in Therapy|January 10, 2018
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational StudyShaloo Gupta, Hongwei Wang, Neil Skolnik, et al.
Diabetes Care|September 25, 2019
Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World StudyJeremy H Pettus, Fang Liz Zhou, Leah Shepherd, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 6, 2023
Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes MellitusJennifer Ken-Opurum, Sistla S S Srinivas, Divya Jain, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 8, 2023
Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation StudyAnkita Chauhan, Mihail Samnaliev, Jennifer Ken-Opurum, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|December 27, 2017
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulinFang Liz Zhou, Lin Xie, Chunshen Pan, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 9, 2007
Ethnic/racial variations in blood pressure awareness, treatment, and controlThomas Giles, Juan M Aranda, Dong-Churl Suh, et al.
Journal of Comparative Effectiveness Research|March 14, 2023
A value-based budget impact model for dronedarone compared with other rhythm control strategiesJennifer Ken-Opurum, Sesha Ss Srinivas, Pratyusha Vadagam, et al.
Clinical Therapeutics|June 21, 2011
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapySuellen M Curkendall, Cheng Wang, Barbara H Johnson, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United StatesVijay N Joish, Fang Liz Zhou, Ronald Preblick, et al.
Advances in Therapy|January 10, 2018
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational StudyShaloo Gupta, Hongwei Wang, Neil Skolnik, et al.
Diabetes Care|September 25, 2019
Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World StudyJeremy H Pettus, Fang Liz Zhou, Leah Shepherd, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 6, 2023
Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes MellitusJennifer Ken-Opurum, Sistla S S Srinivas, Divya Jain, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 8, 2023
Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation StudyAnkita Chauhan, Mihail Samnaliev, Jennifer Ken-Opurum, et al.
Pageof 4